Epidermal Growth Factor Receptor Mutation (EGFR) testing for prediction of response to EGFR-targeting Tyrosine Kinase Inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer : an evidence-based and economic analysis

Medical Advisory Secretariat
Record ID 32010000784
English
Authors' objectives:

The Medical Advisory Secretariat undertook a systematic review of the evidence on the clinical effectiveness and cost-effectiveness of epidermal growth factor receptor (EGFR) mutation testing compared with no EGFR mutation testing to predict response to tyrosine kinase inhibitors (TKIs), gefitinib (Iressa®) or erlotinib (Tarceva®) in patients with advanced non-small cell lung cancer (NSCLC).

Authors' recommendations: Based on moderate quality of evidence, patients with locally advanced or metastatic NSCLC with adenocarcinoma histology being treated with gefitinib in the first-line setting are highly likely to benefit from gefitinib if they have EGFR mutations compared to those with wild-type EGFR. This advantage is reflected in improved PFS, ORR and QoL in patients with EGFR mutation who are being treated with gefitinib relative to patients treated with chemotherapy.Based on low quality of evidence, in patients with locally advanced or metastatic NSCLC who are being treated with erlotinib, the identification of EGFR mutation status selects those who are most likely to benefit from erlotinib relative to patients treated with placebo in the second or third-line setting.
Details
Project Status: Completed
Year Published: 2010
URL for published report: http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/EGFR_20101209.pdf
URL for additional information: http://www.hqontario.ca/en/mas/mas_ohtas_tech_egfr_20101209.html
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Cost-Benefit Analysis
  • Lung Neoplasms
  • Molecular Targeted Therapy
  • Pharmacogenetics
Contact
Organisation Name: Medical Advisory Secretariat
Contact Address: Medical Advisory Secretariat, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 CANADA. Tel: 416-314-1092l; Fax: 416-325-2364;
Contact Name: MASinfo.moh@ontario.ca
Contact Email: MASinfo.moh@ontario.ca
Copyright: Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care (MAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.